1. Executive Summary
The report contained an international marketing plan of a firm, AstraZeneca Plc, that concentrated on the market of the UK. It has analysed the political, economic, social, technological, environmental and legal environment in the UK through the use of PESTEL and has analysed the strengths, weaknesses, opportunities and threats of AstraZeneca through the SWOT framework. The identification of the target market was through the STP model; thus, urban and semi-urban patients with chronic conditions were identified. The alternative that has been proposed is the strategy of joint venture and strategic alliance that can be supported by the locally adjusted marketing mix. Legal, ethical and cultural factors were discussed, the risk management plan, implementation plan and performance measures were put into consideration so that long-term expansion and positive contribution to society in terms of health can be achieved.
The introduction isn't even written yet, but you're sitting there tweaking the font and wording of the title to make it sound smart. Has this happened to you before? You’re not alone!
If you need assistance with your BMA6100-20 International Marketing assignment, you can seek customised BSU assignment help at Locus Assignments.
2. Company Overview
AstraZeneca Plc is a multinational UK-based biopharmaceutical corporation, which has its headquarters in Cambridge, England. The company specialises in research and development and commercialisation of innovative prescription medicines to significant fields of therapeutic focus, such as oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases. AstraZeneca is a corporation that is present in over 100 countries and is also considered scientifically innovative and patient-centred regarding healthcare solutions (Benkiran, 2023).
AstraZeneca is a powerhouse in the UK, along with the global market, with a high volume of investment in research and development (R&D), strategic partnerships, and an efficient product pipeline. The core competencies of the firm include: high-quality clinical research, regulatory experience and excellent global brand image. These advantages will enable AstraZeneca to work effectively in controlled international markets and provide it with a fortress in its intended international growth (Benkiran, 2023).
3. Market Analysis – UK
3.1 PESTEL Analysis – UK
Political:
The UK has a predictable market concerning the pharma companies because it is stable in the political environment and has well-established institutions. The National Health Service (NHS) is one of the most effective institutions within the healthcare policy due to the universal healthcare services offered and the role it plays in regulating the procurement of pharmaceuticals. The programs of Governments, such as Accelerated Access Collaborative and NHS long-term plan, are aimed at innovating pharmaceutical solutions, and, therefore, AstraZeneca can offer new solutions in oncology, respiratory, heart and treatment of rare diseases. Brexit has brought some changes in the regulations, particularly in the approval of pharmaceuticals and import/export logistics; however, the UK still has a strict and transparent regulatory system (Mogaji, 2025).
Economic:
The UK is a developed economy whose income is approximately 50,000 per capita consumption, and the expenditure on health is estimated to be approximately 10 per cent of the GDP. The pharmaceutical industry is a significant component of the economy that has large R&D investment and governmental support in the form of taxation. The purchasing power of the market in the UK will be high, yet the cost-cutting efforts of the NHS and the budget constraint suggest that prices will be put under pressure.
Social:
The UK is a population with an increasing age where more than 18 per cent of the population is aged 65 years and over, leading to a high prevalence of chronic diseases such as cancer, diabetes and cardiovascular diseases. There is high health awareness among the population, and patients have now insisted on innovative therapies and individualised medicine, resulting in improved treatment outcomes (Mogaji, 2025).
Technological:
The UK has a highly developed healthcare and pharmaceutical system. Heavy investment in medical research, digital health platforms and clinical trials ensures innovation. Good universities in the world, biotech centres (e.g. Cambridge and Oxford) and availability of advanced manufacturing plants benefit AstraZeneca in the UK. Technology also supports precision medicine, artificial intelligence in drug discovery and patient monitoring, and this will make AstraZeneca even stronger in offering personalised therapy.
Environmental:
Environmental sustainability is becoming of high importance in the UK pharmaceutical industry. The rules force the companies to dispose of garbage, reduce the emission of carbon dioxide, and adopt sustainable ways of production. AstraZeneca can improve its corporate social responsibility and brand image by one of the ways through its alignment with the national environmental goals and adhering to green supply chain practices.
Legal:
Ethical requirements include clinical trial authorisation, drug safety, and drug pricing and intellectual property safeguard. With the rising generic competition and biosimilars, AstraZeneca will be forced to work under a complex NHS procurement law, anti-bribery and patent laws.
3.2 SWOT Analysis AstraZeneca in the UK
Strengths:
-
Good foreign brand, and UK history.
-
Building professional relationships with the NHS and academic institutions (Kopilaš et al., 2024).
Weaknesses:
-
The price of the drugs in comparison with generics is high and will, therefore, limit access through the budget constraints of the NHS.
-
High reliance on regulatory approval for the introduction of new products.
Opportunities:
-
NHS initiatives that support an expeditious adoption of new technologies.
-
Partnerships with the biotech firms and the digital health startups in the UK.
Threats:
-
The increase in competitiveness within the NHS cost-containment and generic competition.
-
Regulatory divergence that is likely to occur upon Brexit and affects market access (Kopilaš et al., 2024).
SWOT and PESTLE both done! Phew!! But the assignment isn’t even half complete! Need an extra hand with your BMA6100-20 International Marketing assignment? Locus Assignments’ professional writers can provide you with end-to-end support with assignment writing, research, analysis, editing, proofreading, and referencing. Order Bath Spa University assignment help today!
3.3 Rationalisation of the market choice
The UK is a strategically important market for AstraZeneca due to its excellent healthcare infrastructure, massive spending on research and development and innovation-facilitating environment. The rising number of people over the age of 65 and the rising number of chronic diseases put a strain on the necessity to possess complex therapeutics. In spite of the financial shortfall and legislative pressures, the brand name, good clinical evidence, and local presence will ensure that AstraZeneca will be in a position to retain and gain market share. Furthermore, the UK is a major base of activities in Europe, clinical trials and business partnerships that justify its long-term significance in the global expansion strategy of AstraZeneca (Benkiran, 2023).
4. Identification of target market -STP Model (UK)
Segmentation
Such variables as demographic, geographic, psychographic and behavioural ones can be applied to the UK market of AstraZeneca and divide it into segments:
Demographic: The UK is an ageing nation with over 18 per cent of the population aged 65 years and above, and also a high occurrence of chronic diseases such as cancer, cardiovascular, respiratory and metabolic diseases. The key consumers of sophisticated pharmaceutical treatments are adults (35 years to 75 years old) in the middle- to high-income groups or those privately covered by healthcare. In other instances, like the use of gender-specific marriages in the treatment of breast, prostate or lung cancer, there may be gender-specific marriages (IVĂNESCU et al., 2024).
The areas of high priority are the urban and semi-urban areas in England, Scotland, Wales and Northern Ireland because there are high levels of hospitals, research centres, and specialist clinics in these areas. There are tertiary care hospitals, cancer centres and specialised research centres in major cities like London, Manchester, Bristol, and Edinburgh. The number of healthcare services and the network of professionals to serve the patients are also high in these regions, and it is easy to enter the market (IVĂNESCU et al., 2024).
Psychographic: The patients of the UK are increasingly becoming health-conscious, they are increasingly adhering to the prescribed treatment, and are more interested in clinically proven and innovative therapies. Psychographic will identify patients who have put values on personalised care, technology-based health care and patient support programmes. In addition, the family members and the other caregivers are likely to influence the treatment options, especially among the older patients who have long-term or complex illnesses (Subramaniam, 2022).
Behavioural: Behavioural segmentation considers the interactions between the patients with the healthcare systems, the number of visits to the hospital and contact with long-term medication. This includes patients who visit experts on a regular basis, participate in clinical trials, or use electronic health resources to follow up and perform telemedicine. Early investigators of innovative therapies and biologics/precision medicine patients represent a powerful behavioural target market to AstraZeneca (Akkaya, 2021).
Targeting
The focused differentiation strategy will be adopted by AstraZeneca in the UK and specifically among the patients with high clinical value but requiring specialised treatments. The key target audiences are:
1. Late or chronic oncology patients, with a high percentage of them currently in hospitals or specialists' care (Rachmad, 2024).
2. This category was patients who were registered as requiring long-term care, such as diabetes, high blood pressure or hypercholesterolemia.
3. Patients who have respiratory conditions and severe asthma or chronic obstructive pulmonary disease (COPD), particularly those who are under the treatment of an expert.
By directing the prescription of the hospitals and specialists, AstraZeneca has direct access to the most likely victims of their innovative therapies, and consequently, clinic impact and market effectiveness are heightened (Rachmad, 2024).
Positioning
AstraZeneca will create a presence of a patient-centric, science-driven, pharmaceutical company in the UK market that will deliver innovative and clinically validated medicines, which will offer a quantifiable health effect. Part of the key positioning attributes includes:
-
Innovation and R&D excellence: The emphasis was placed on the oncological, respiratory and cardiovascular therapy leadership of the company with the help of the strong evidence of clinical trials.
-
Quality and trust: Developing the image of AstraZeneca as an ethical, responsible enterprise that provides life-saving drugs (Saqib, 2021).
Strategic Implications
AstraZeneca can establish itself as a trusted leader of innovation and differentiate against generic rivals and address the evolving healthcare trends through the comprehensive segmentation of the UK market, focus on the high-value patient groups, and position itself as such. The STP strategy will support the targeted marketing programs, including the hospital-specific advertising, collaboration with medical staff, online-based approaches to communication, and patient support initiatives, which will ensure effective market penetration and long-term market expansion in the UK (Saqib, 2021).
5. Marketing Strategy Development- UK
Market Entry Strategy
AstraZeneca is a popular brand in the pharmaceutical market of the UK and has a strong history, research and collaboration with the NHS. The marketing strategy is anchored in the development of penetration of the market, the establishment of a closer relationship with hospitals and specialists, and the enhancement of access programmes to patients. Creative partnerships with UK-based biotech corporations, speciality clinics and NHS trusts will assist in the implementation of novel therapies as well. In addition, it is possible to collaborate with digital health providers and telemedicine websites and engage patients, improve adherence to the outcomes, and support the measurement of the results (Chaganti, 2023).
The Competitive Positioning Strategy
Differentiation strategy approach will also be employed by AstraZeneca in the UK by emphasising clinical innovation and patient-centred care, as well as focusing on scientific leadership. Key elements include:
-
Innovation and R&D leadership: The Company is able to take advantage of the strong oncology, cardiovascular and respiratory portfolio and provide the clinically proven therapies to satisfy the unmet medical needs.
-
Patient support and access programmes: Enhancing adherence to educational, digital and personal care programmes. Its programmes targeting old patients and patients with chronic conditions are also consistent with NHS patient-centric models of care.
-
Evidence-based marketing: Providing clinical trials, real-world data and outcome research to increase confidence in medical professionals and NHS decision-makers (Chaganti, 2023).
Brand Strategy
The hybrid branding strategy, which is the global brand standard and the localised communication, will be used by AstraZeneca to attract the UK healthcare stakeholders:
-
The international similarity: It will look like all the markets share the same values of the brand, like scientific excellence, innovation, and ethical integrity.
-
Local adaptation: The communication and interaction will be grounded in UK-specific healthcare priorities, NHS guidelines, and cultural aspects. The promotion will be done through digital platforms, professional conferences and continuing medical education (CME) and the marketing campaigns will be directed towards medical professionals and patients (Horgan et al., 2024).
Customer Relationship Management (CRM)
Good CRM is the core of the UK strategy of AstraZeneca. This includes:
-
Creating positive relationships with the medical practitioners in the hospitals through hospital liaison teams and specialist medical representatives.
-
Communication with patients through support programmes and health education schemes, as well as through electronic portals to create confidence and improve adherence to treatment (Horgan et al., 2024).
6. Marketing Mix – 4 Ps (UK)
Product
The product strategy adopted by AstraZeneca in the UK is to provide innovative, clinically proven medicines that meet unexpressed healthcare needs in the sectors of oncology, cardiovascular, respiratory and metabolism. The demand of the market in the UK does not require many changes to the formulation, as the products already comply with the requirements of the MHRA. However, their local packaging and labelling will be done to match the UK standards in order to provide unambiguous patient data and make it more convenient to use by elderly audiences.
The patient support programme is a product enhancement, and this is significant to the UK healthcare environment. They include adherence programs for chronic disease patients, educational materials, online services to control the process of treatment and special helplines (Cai et al., 2025).
Price
The most significant determinants of price in the UK are the NHS procurement policies, cost-effectiveness reviews (e.g., NICE reviews) and price-cutting mechanisms. Tier pricing will be employed by AstraZeneca:
-
NHS pricing: Competitive pricing in accordance with the NICE guidelines in order to enable it to be incorporated into the formularies and reimbursement schemes.
-
Pricing by the private sector: The pricing of the private sector will be in the form of a premium, which will be pegged on innovation, support to the patients and patient outcomes.
-
Patient access programmes: Financial assistance or co-payment programmes to patients undergoing therapy that is of high cost, in order that it is affordable and utilised (Hung and Yen, 2022).
Place (Distribution)
In the UK, distribution is meant to deliver quality delivery to the hospitals, specialist clinics and the private healthcare providers. Key elements include:
-
Distribution by hospital and specialist clinics: NHS trusts, hospital pharmacies and centres of tertiary care: Direct supply deals.
-
Partnership: The partnership will encompass independent specialist clinics and collaborations with the private hospital groups.
-
Cold-chain logistics: Refrained from conditions that are stable and biologics (speciality medicines) sensitive, such that the product will not get damaged during the production process, all the way to the patient (Hung and Yen, 2022).
Promotion
The marketing strategy AstraZeneca adopts in the UK is an intricate one that integrates professional and patient education, as well as population awareness:
-
Contact with medical representatives: Specialist liaison group operates and interacts with physicians, pharmacists and hospital staff, and provides them with clinical evidence, treatment guidelines, and patient support tools.
-
Telehealth and online marketing: Webinars, online CME courses and online channels: It is an opportunity to provide a chance to speak to professionals and patients, particularly in remote areas, with ease.
-
Processes: The processes include health awareness campaigns and educational campaigns with the population targeted at the early detection, treatment adherence, and prevention of chronic diseases, which are also consistent with the NHS priorities.
-
Corporate social responsibility (CSR): The collaboration with patient advocacy, health research, and local health support is one of the aspects that make AstraZeneca a more responsible and patient-friendly corporation (Rachmad, 2024).
Analyzing and writing the 4Ps section of a marketing assignment can make you go like— ‘I don't care about marketing mix, just get this assignment completed!!’
But your assignment still asks you for it! Let Locus Assignments guide you. With AI-free and plagiarism-free writing services, we provide Bath Spa University and Elizabeth School of London students with customised assignment help to handle difficult modules such as BMA6100-20 International Marketing.
7. Legal and Ethical Requirements -UK
A high legal and ethical framework under which the operations of AstraZeneca in the UK are guided is meant to ensure patient safety, regulation and ethical business practices. These needs are supposed to be interpreted and adhered to so that they are confided in by the healthcare providers, patients and regulators.
Legal Considerations
1. Regulatory Compliance: All the medicines in the UK must comply with the regulations stipulated by the Medicines and Healthcare products Regulatory Agency (MHRA). This includes the procurement of marketing approvals and adherence to the pharmacovigilance standards, and all clinical trials must be in accordance with the Good Clinical Practice (GCP). AstraZeneca will also need to argue out the new regulatory procedures, which were previously structured by the European Medicines Agency (EMA) after Brexit (Albrecht et al., 2023).
2. Intellectual Property (IP) and Patents: It is noteworthy to safeguard innovation. AstraZeneca must safeguard the patents of its new therapies and prevent potential risks of generic entry or the threat of biosimilar products. The protection of IP is high, which implies that the company can recover the investment in the field of R&D and yet innovate.
3. Pricing and Reimbursement Regulations: By following the NHS drug pricing deals, Patient Access Schemes and other reimbursement schemes, AstraZeneca should ensure that its operations within the market are not illegal and that they remain sustainable in the market (Albrecht et al., 2023).
Ethical Considerations
1. Patient-Centric Care: AstraZeneca are of the opinion that they deliver medicines that improve the outcome of the patient, and they are interested in safety, efficacy, and accessibility. Patient information must be precise, understandable and factual (Juricic and Market, 2025).
2. Clinical Research Transparency: Clinical trial data must be publicly accessible to be applied and utilised in a way that enhances scientific integrity and should be presented to enable informed decisions on the part of healthcare providers and patients.
3. Responsible Marketing: Marketing efforts should be correct, fair and in line with the Association of British Pharmaceutical Industry (ABPI) code of practice. AstraZeneca is not supposed to make exaggerated claims and heavy product promotions (Juricic and Market, 2025).
8. Risk Management Plan – UK
The UK pharmaceutical market is very competitive and highly regulated at AstraZeneca. The strategy of risk management ought to be proactive to lessen the challenges and render operations sustainable (Jenkins et al., 2022).
Regulatory Change is a high threat, and is linked to the modification of the MHRA and NICE guidelines, the occurrence of regulatory divergence in the case of Brexit and the reimbursement policy. AstraZeneca would reverse this by monitoring the changes in regulations, the local regulations and local legal expertise, in addition to ensuring that it conforms to approvals, pharmacovigilance and pricing regulations.
Pricing and cost-containment pressure are another area of high risk since the NHS is concerned with cost-effectiveness. The mitigation strategies would include flexible pricing schemes provision in line with the demand of the NHS and the private sector, participation in Patient Access Schemes, and collaboration with innovation funds to ease market entry (Jenkins et al., 2022).
In the UK market, the competition for the products of generics and Biosimilars is high. By leveraging its strong R&D pipeline, patent protection, differentiation of clinical evidence, and by offering patient support programmes, AstraZeneca will be in a position to overcome this risk in bringing value added to the medicine (Alkaraan et al., 2023).
Media coverage and Ethics should be tamed. The company will be able to maintain patient, health care provider, and regulatory trust by providing transparency to clinical data and adhering to the ABPI codes of ethical marketing and participation in CSR and public health programs.
The Supply Chain Disruptions are addressed using the ownership of strong logistics networks, like the cold-chain network case in biologics and establishing multiple supplier networks to reduce the operational risk.
Cultural and Stakeholder Misalignment is dealt with through constant contact with NHS decision-makers, healthcare professionals, and patient advocacy groups in such a way that communication and efforts are directed to align with the UK healthcare priorities (Alkaraan et al., 2023).
You logged on thinking you’d finish in thirty minutes before dinner, only to read the submission requirements and feel your heart drop. Now, it has been three hours of writing— and you're nowhere near completion.
Avail expert assignment help services for Bath Spa University assignments and excel in your BMA6100-20 International Marketing!
You can also avail our other services including dissertation help, thesis help, essay writing services, coursework help, and more— AI-free, and plagiarism-free, from Locus Assignments!
9. Implementation Plan – UK
In the case of the implementation plan used by AstraZeneca in the UK, the implementation process is based on planned, step-by-step activities to allow the successful implementation of its marketing strategy without violating regulatory standards and fulfilling the needs of the patients (Jemielniak and Krempovych, 2021).
Year 1: Foundation and Preparation
The tasks will involve effective market research, stakeholder mapping, and needs assessment among NHS trusts and within the private healthcare providers. Regulatory submissions to MHRA and interaction with the NICE on reimbursement assessments will take precedence. It will be partnered with UK biotech companies, hospitals and digital health providers in strategic ways to adopt the products and support the patient access programmes (Jemielniak and Krempovych, 2021).
Year 2: Launching and promotion of the product
Hospitals, specialist clinics, and organisations in the private sector will be used to introduce key products. The promotion will be targeted at healthcare professionals through medical liaison teams, online promotion, and continuing medical education (CME) programs. They will be initiated by the introduction of patient support programmes and educational campaigns, which will increase adherence and awareness of disease management (Cross et al., 2021).
Year 3: Growth and streamlining
After initial adoption, AstraZeneca will increase outreach to secondary cities and other NHS Trusts based on the early adoption. The performance metrics, the stakeholder feedback, and patient outcomes are going to be used in the process of optimising marketing activities. The constant contact with regulatory authorities, medical practitioners, and patient communities will lead to continuity in maintaining and keeping it in line with the UK healthcare priorities (Cross et al., 2021).
10. Performance Metrics – UK
AstraZeneca will use a combination of financial, operational, and clinical performance measures. The significant ones include market share expansion both in the NHS and in the private market, revenue and profitability in the designated therapeutic domains, success with the regulatory side in the form of MHRA approvals and inclusion in NICE guidelines. The rate of adoption and prescription of healthcare professionals will be considered as engagement efficacy, and patient adherence rate and satisfaction as the effects of support programmes. The degree of brand recognition, participation in digital health schemes and NHS stakeholder feedback are other indicators. The continuous evaluation will ensure the prompt modification of the strategy that will ensure the long-term development and improvement of the healthcare outcomes in the UK (Safi, 2021).
11. Conclusion
AstraZeneca, in the case of the UK, one of the core blocks of its global business is the UK, which provides a stable regulatory environment, well-established R&D and a superior healthcare system through the NHS. This report brings out the fact that, by exploiting the scientific capability, robust clinical trial networks and regulatory experience within the UK, global expansion will be easier and operational leadership maintained in the local environment. A country-based leader, AstraZeneca can also become a competitor and build a strong brand and foundation on innovation, ethical practices, and patient-centric solutions in the UK to further its growth abroad.
Under immense pressure to complete your BMA6100-20 International Marketing assignment? Get personalised Bath Spa University assignment help— tailored to your assignment brief, deadline, and submission requirements. Order now!
